Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis

Keidel, Sarah; McColl, Aubretia; Edmonds, Sally

doi:10.1136/bcr.10.2011.4935

Cited by 21 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early diagnosis of RP is even more challenging [1]. Laboratory investigations in this case revealed increased CRP, in accordance with previous studies [4]; interestingly, we also found an increased ferritin level, consistent with the findings of Fujiki et al [5].…”

Section: Discussionsupporting

confidence: 92%

Stenosis of the Subglottic Trachea Revealing Relapsing Polychondritis of a Young Adult

Euch¹,

Mahfoudhi²,

Gorsane³

et al. 2015

IJCM

View full text Add to dashboard Cite

Relapsing polychondritis is a rare inflammatory disease involving essentially cartilaginous structures. Other systemic manifestations can be encountered as the eye and ear disturbance. Aortic aneurysms affect few cases. If affection of airway cartilages occurs, prognosis may be worsened by eventual stenotic lesions. We report a 22-year-old woman with Relapsing polychondritis. When she was referred to our hospital 4 weeks after the onset of respiratory symptoms, she was having severe breathing difficulty. Immediate tracheostomy followed by steroid therapy improved her respiratory condition, although the treatment was complicated because of her diabetes. While airway involvement of Relapsing polychondritis can be life threatening, it is curable with steroid therapy. Clinicians should keep in mind that airway obstruction could be caused by this disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Stenosis of the Subglottic Trachea Revealing Relapsing Polychondritis of a Young Adult

Euch¹,

Mahfoudhi²,

Gorsane³

et al. 2015

IJCM

View full text Add to dashboard Cite

show abstract

“…As new drugs are used, isolated case reports of drug‐induced Sweet syndrome continuously appear in the literature. Dermatologists should know that cases of Sweet syndrome have been attributed to isotretinoin, adalimumab, vemurafenib and ipilimumab, as well as bortezomib, azathioprine and antibiotics, among other drugs.…”

Section: Sweet Syndromementioning

confidence: 99%

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Wallach¹,

Vignon‐Pennamen

2015

Br J Dermatol

View full text Add to dashboard Cite

Pyoderma gangrenosum, a dramatic ulcerative skin disease, and Sweet syndrome, a papular dermatosis, were described independently. It was subsequently shown that they share many characteristics, including clinical overlap and the frequent association with multisystemic disorders. The group of the neutrophilic dermatoses encompasses these two dermatoses, as well as other conditions having in common an aseptic neutrophilic infiltrate predominating in the epidermis and/or the dermis and/or the subcutis. Some patients also experience neutrophilic infiltrates in other organs, defining the neutrophilic disease. Recent research suggests that the neutrophilic dermatoses could be considered as the cutaneous expression of the autoinflammation, an aberrant hyperproduction of interleukin-1. Autoinflammation is responsible for monogenic diseases, and is also involved in the mechanism of many polygenic conditions, including the neutrophilic dermatoses.

show abstract

“…Granulocyte colony stimulating factor (G-CSF) is considered most common among them while other drugs include minocycline, trimethoprim/sulfamethoxazole, HRT/ OCP, furosemide, celecoxib, azathioprine. 10 TNF-I have also been associated with development of SS 11,2 and PG lesions. 12 Similar unexpected reactions have been described with infliximab use in UC 13 and RA 14 ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience

Sehgal¹,

Stratman²,

Cutlan³

2018

Clin Med Res

View full text Add to dashboard Cite

Biologic agents are regarded as an effective treatment for a variety of autoimmune diseases. These drugs have an acceptable safety and tolerability profile, although an increasing number of autoimmune conditions have been reported with their use. Additionally, a variety of cutaneous diseases have been associated with their use. Here we report our experience of adverse cutaneous events with the use of biologic agents. An alternative explanation for patients presenting with adverse cutaneous events including drug interactions must be carefully investigated.

show abstract

Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis

Cited by 21 publications

References 14 publications

Stenosis of the Subglottic Trachea Revealing Relapsing Polychondritis of a Young Adult

Stenosis of the Subglottic Trachea Revealing Relapsing Polychondritis of a Young Adult

Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses

Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience

Contact Info

Product

Resources

About